ME/CFS Through the Lens of Universal Disease Mechanisms
Most diseases do not invent new biology — they dysregulate mechanisms that are shared across the entire spectrum of human pathology. The body can respond to injury, infection, or metabolic insult in only a finite number of ways (Ayres 2020) (Quintero 2014). This observation, recurring across network medicine, systems pathobiology, and medical education reform proposals, suggests that the ~17,000 named diagnostic categories in ICD-11 are not 17,000 independent phenomena, but rather different combinatorial expressions of a much smaller set of fundamental mechanism families — roughly 20 in total — each instantiated in different tissues, at different severities, and triggered by different initiating events.
This chapter provides a systematic survey of those mechanism families and assesses where ME/CFS stands within each. The taxonomy is built inductively from the pathophysiology literature — no single published framework covers all of them at this specificity — and represents the paper’s own synthesis. For each family we enumerate the concrete mechanisms within it, assess the state of ME/CFS-specific evidence, and cross-reference the dedicated chapter where the evidence is treated in depth.
The goals are twofold. First, completeness: ensuring the paper does not inadvertently ignore a mechanism family simply because it has attracted little ME/CFS-specific research attention. Second, positioning: situating ME/CFS within the broader disease landscape, which is essential for the cross-disease comparisons in Speculative Mechanistic Hypotheses and for the research gap agenda in Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026).
| # | Family | Evidence in ME/CFS | Status |
|---|---|---|---|
| 1 | Energy and metabolic regulation | Mitochondrial OXPHOS; PDH/PDK block; NAD⁺ | Established |
| 2 | Redox and oxidative balance | ROS, nitrosative stress, lipid peroxidation | Established |
| 3 | Ion channel and membrane transport | TRPM3 channelopathy; RBC membrane stiffness | Established |
| 4 | Immune activation and cytokine signalling | NK exhaustion; cytokine excess; complement | Established |
| 5 | Autoimmunity and molecular mimicry | Anti-β2AR; anti-M3R; anti-TRPM3 | Established |
| 6 | Coagulation and haematological | Fibrin microclots; platelet hyperactivation | Probable |
| 7 | Vascular and endothelial | Endothelial dysfunction; cerebral hypoperfusion | Established |
| 8 | Autonomic and peripheral nervous system | Baroreflex failure; POTS; small fiber neuropathy | Established |
| 9 | Neuroendocrine and hormonal | HPA blunting; low T3; sex hormone dysregulation | Probable |
| 10 | Neurological and thalamocortical | Neuroinflammation; E/I imbalance; alpha intrusion | Established |
| 11 | Amino acid and neurotransmitter metabolism | Tryptophan/IDO/kynurenine; serotonin depletion | Probable |
| 12 | Genomic and epigenetic regulation | Methylation signatures; telomere attrition | Established |
| 13 | Protein homeostasis and degradation | HSP dysregulation; autophagy block (ATG13) | Emerging |
| 14 | Cell death and senescence | NK/T cell exhaustion; immunosenescence; SASP | Emerging |
| 15 | Gut-microbiome-immune axis | Dysbiosis; leaky gut; LPS translocation | Probable |
| 16 | Viral persistence and immune evasion | EBV/HHV-6 reactivation; enterovirus persistence | Probable |
| 17 | Structural and tissue integrity | Skeletal muscle damage; SFN fiber loss; hEDS overlap | Emerging |
| 18 | Transcriptional and nuclear signalling | NF-κB (inferred); Nrf2 (indirect); VDR | Theoretical |
| 19 | Purinergic and danger signalling | ATP-DAMP/P2X7; CDR hypothesis; NLRP3 (unstudied) | Theoretical |
For patients: read the overview table to see the breadth of affected mechanisms and the family sections relevant to your symptoms (e.g., energy, immune, vascular). Each family cross-references its full chapter.
For caregivers: read the overview table for a one-page map of the disease’s systems. Individual family detail is best accessed via the cross-referenced chapters.
For clinicians: use the overview table and each family’s evidence-status line as a rapid reference; the cross-references route to the in-depth chapter for each mechanism.
For researchers: read the full family sections for completeness — the emerging/theoretical families (protein homeostasis, cell death, purinergic) flag the least-studied mechanisms and the research-gap agenda feeding Chapter Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026).
1 Contents
- Family 1: Energy and Metabolic Regulation
- Family 2: Redox and Oxidative Balance
- Family 3: Ion Channel and Membrane Transport
- Family 4: Immune Activation and Cytokine Signalling
- Family 5: Autoimmunity and Molecular Mimicry
- Family 6: Coagulation and Haematological
- Family 7: Vascular and Endothelial
- Family 8: Autonomic and Peripheral Nervous System
- Family 9: Neuroendocrine and Hormonal Regulation
- Family 10: Neurological and Thalamocortical
- Family 11: Amino Acid and Neurotransmitter Metabolism
- Family 12: Genomic and Epigenetic Regulation
- Family 13: Protein Homeostasis and Degradation
- Family 14: Cell Death and Senescence
- Family 15: Gut-Microbiome-Immune Axis
- Family 16: Viral Persistence and Immune Evasion
- Family 17: Structural and Tissue Integrity
- Family 18: Transcriptional and Nuclear Signalling
- Family 19: Purinergic and Danger Signalling
- Family 20: Inflammation Resolution and Lipid Mediators
- Synthesis: The Mechanism Landscape of ME/CFS